

PI breast cancer, and monitoring cancer progression in a patient -
 XX
 PS Claim 4; Page 177; 187pp; English.
 XX

The present sequence is given in a specification relating to compositions and methods for the treatment and diagnosis of breast cancer. Nucleotide sequences that are preferentially expressed in breast tumor tissue, and the polypeptides encoded by such nucleotide sequences, are used in compositions and vaccines to inhibit the development of cancer, especially breast cancer. The progression of a cancer may be monitored by carrying out detection of tumor specific antigens at subsequent time points and/or CD8⁺ T-cells isolated from the cancer patient may be treated with tumor-specific polypeptides, polynucleotides encoding the polypeptides or antigen presenting cells expressing the polypeptides. The cells are then administered to the patient to inhibit development of cancer.

Sequence 1155 BP; 346 A; 253 C; 297 G; 259 T; 0 other;

Query Match: 100 %, Score 1155; DB 21; Length 1155;
 Best Local Similarity 100.0%; Pred. No. 0;

Matches 1155; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

OY 1 atgaggttggatgattcattcattccgacacccctctctgtaagaacgcatlgtgctc 60
DB 1 atgaggttggatgattcattcattccgacacccctctctgtaagaacgcatlgtgctc 60
OY 61 aagaaacaaatggaacatgctgctgctgctgctgctgctgctgctgctgctgctgctg 120
DB 61 aagaaacaaatggaacatgctgctgctgctgctgctgctgctgctgctgctgctgctg 120
OY 121 agcaacgtggacactctggaacacacacactctgctgctgctgctgctgctgctgctg 180
DB 121 agcaacgtggacactctggaacacacacactctgctgctgctgctgctgctgctgctg 180
OY 181 atggcaagtgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctg 240
DB 181 atggcaagtgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctg 240
OY 241 ggcgtctctggaacacacacacactctgctgctgctgctgctgctgctgctgctgctg 300
DB 241 ggcgtctctggaacacacacacactctgctgctgctgctgctgctgctgctgctgctg 300
OY 301 tgggtgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctg 360
DB 301 tgggtgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctg 360
OY 361 ggaacacacacacacacacacacacacacacacacacacacacacacacacacacac 420
DB 361 ggaacacacacacacacacacacacacacacacacacacacacacacacacacacac 420
OY 421 gacaaactcacaagctgctgctgctgctgctgctgctgctgctgctgctgctgctgct 480
DB 421 gacaaactcacaagctgctgctgctgctgctgctgctgctgctgctgctgctgctgct 480
OY 481 ctgaggaacacacacacacacacacacacacacacacacacacacacacacacacacac 540
DB 481 ctgaggaacacacacacacacacacacacacacacacacacacacacacacacacacac 540
OY 541 tctgacacacacacacacacacacacacacacacacacacacacacacacacacacac 600
DB 541 tctgacacacacacacacacacacacacacacacacacacacacacacacacacacac 600
OY 601 gtccttcaaaacacacacacacacacacacacacacacacacacacacacacacacac 660
DB 601 gtccttcaaaacacacacacacacacacacacacacacacacacacacacacacacac 660
OY 661 tgggttcaaaacacacacacacacacacacacacacacacacacacacacacacacac 720
DB 661 tgggttcaaaacacacacacacacacacacacacacacacacacacacacacacacac 720

```

```

OY 721 accactgcaactacacacacacacacacacacacacacacacacacacacacacacac 780
DB 721 accactgcaactacacacacacacacacacacacacacacacacacacacacacacac 780
OY 781 tgggttcaaaacacacacacacacacacacacacacacacacacacacacacacacac 840
DB 781 tgggttcaaaacacacacacacacacacacacacacacacacacacacacacacacac 840
OY 841 catgaacacacacacacacacacacacacacacacacacacacacacacacacacacac 900
DB 841 catgaacacacacacacacacacacacacacacacacacacacacacacacacacacac 900
OY 901 ctggatagaataggaagacacacacacacacacacacacacacacacacacacacacac 960
DB 901 ctggatagaataggaagacacacacacacacacacacacacacacacacacacacacac 960
OY 961 gtcacgttcaactggaacacacacacacacacacacacacacacacacacacacacac 1020
DB 961 gtcacgttcaactggaacacacacacacacacacacacacacacacacacacacacac 1020
OY 1021 gtcagagagatgattgcttcaactacacacacacacacacacacacacacacacacac 1080
DB 1021 gtcagagagatgattgcttcaactacacacacacacacacacacacacacacacacac 1080
OY 1081 aagaaacacacacacacacacacacacacacacacacacacacacacacacacacac 1140
DB 1081 aagaaacacacacacacacacacacacacacacacacacacacacacacacacacac 1140
OY 1141 accaaacacacacacacacacacacacacacacacacacacacacacacacacacac 1155
DB 1141 accaaacacacacacacacacacacacacacacacacacacacacacacacacacac 1155

RESULT 2
AAA06598
ID AAA06598 standard; cDNA; 1155 BP.
AC AAA06598;
XX
XX
XX 13-JUN-2000 (first entry)
XX
XX Human immunogenic prostate tumor protein cDNA sequence SEQ ID NO:373.
XX
XX Human; prostate cancer; diagnosis, tumor, gene therapy, detection;
XX immunogenic; cytosolic; vaccine; ss
XX
XX Homo sapiens.
XX
XX W0200004149-A2.
XX
XX 27-JAN-2000.
XX
XX
XX 14-JUN-1999; 99W0-S15838.
XX
XX
XX 14-JUN-1998; 98US-0116453.
XX
XX 14-JUN-1998; 98US-0116134.
XX
XX 23-SEP-1998; 98US-0159812.
XX
XX 23-SEP-1998; 98US-0159812.
XX
XX 15-JAN-1999; 99US-0232149.
XX
XX 15-JAN-1999; 99US-0232880.
XX
XX 09-APR-1999; 99US-0288946.
XX
XX
XX (CORI-) CORIXA CORP.
XX
XX
XX Dillon DC, Harlocker SL, Yeagin T, Xu J, Mitcham JL,
XX
XX WPI; 2000-171268/15.
XX
XX New polypeptide useful for treating and diagnosing prostate cancer
XX comprises an immunogenic portion of prostate tumor protein -
XX
XX Claim 50; Page 222; 263pp; English.
XX

```


[illegible][illegible]

```

DB 241 agcgttcttggagatcagagatgactctctcttgaagatctccagagatgagagag 308
      |||
UY 301 tggatcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 348
      |||
DB 361 tggatcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 360
      |||
UY 421 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 428
      |||
DB 421 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 480
      |||
UY 481 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 540
      |||
DB 541 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 600
      |||
UY 601 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 660
      |||
DB 661 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 720
      |||
UY 721 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 780
      |||
DB 781 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 840
      |||
UY 841 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 900
      |||
DB 901 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 960
      |||
UY 961 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 1020
      |||
DB 1021 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 1080
      |||
UY 1081 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 1138
      |||
DB 1138 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 1198
      |||

```

```

XX 0S Homo sapiens.
XX PN W200114402 A2.
XX 17-MAY-2001.
XX 09-NOV-2000. 2695WD-US30504.
XX PE 12-NOV-1999. 990S-0419313.
XX PR 18-NOV-1999. 990S-0443686.
XX PA (OIRI-) OIRIXA OIRP.
XX PI Xu J, Dillon PC, Mitcham JL, Harlocker SL, Jiang Y, Reed SB;
XX PC Kates MD, Felker MB, Paul JA, Day CH, Szelig YAM, Ward A;
XX DB WJ. 2001 308785/82.
XX PT Isolated polypeptide comprising at least an immunogenic portion of a
XX PT prostate specific protein, useful in the diagnosis and therapy of
XX PT prostate cancer.
XX PS Claim 31, Page 247-248, 325pp; English.
XX SS The present invention describes an isolated polypeptide (P) comprising
XX CC at least an immunogenic portion of a prostate-specific protein, or its
XX CC variant. Also described are polypeptides (N) encoding (P), (P) and
XX CC (N) have cytotoxic activity and can be used in vaccine production.
XX CC The polypeptides, nucleic acids and antibodies from the present
XX CC invention are useful in the diagnosis and therapy of prostate cancer.
XX CC Prostate specific protein (PSP), P712P, P774P, P776P and P777P are
XX CC in a family of proteins known as the "P" family.
XX CC Prostate specific antigen (PSA) P5015 was located on
XX CC chromosome 1. AAH8471 to AAH8514 and AAC9900 to AAC9907 represent
XX CC polypeptide and polypeptide sequences used in the exemplification
XX CC of the present invention.
XX SQ Sequence 2000 bp: 698 A; 488 G; 489 G; 425 T; 0 other;

```

```

Query: Mat h 78.0%, Score 1131.6, E=22, Length 2000;
Best Local Similarity 99.6%, Pred. No. 0;
Matches 1134; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

[illegible][illegible]

[illegible][illegible]

Sat Mar 9 09:57:24 2002

us-09-699-295-301_1.rng

[illegible][illegible]

[illegible][illegible]

[illegible][illegible]

Sat Mar 9 09:57:25 2002

us-09-699-295-301_1.rst

Page 14

Search completed: March 9, 2002, 01:50:43
Job time: 4722 sec

• • •

[illegible][illegible]

[illegible]

RESULT 1
 AAR06/15
 10 AAR06/15, standard; 670RA, 2000 BP.

XX	AAB93715;
XX	
DE	04-OCT-2001 (first entry)
XX	
HE	Human prostate specific RNA sequence B0483196 variant #9.
XX	
KW	Homo sapiens; prostate cancer; prostate specific; diagnostics; screening
RW	Cytoskeletal gene therapy; metastasis; ssr.
OS	Homo sapiens .
XX	
PN	W0200151633-A2.
XX	
PD	19-JUL-2001.
XX	
PF	16-JAN-2001; 2001WO-US01574.
XX	
PR	14-JAN-2000; 2000US-0483672.
XX	
PA	(CORI-) CORXA CORB.
XX	
F1	Xu J., Patten M., Mitchell JL., Bartelker SL., Jiang Y., Reed SG.,
F1	Kalos MP., Papou GE., Day EH., Kotter MW., Strick VA., Stealey VAW:
F1	Wang A., Meador MJ;
XX	
DR	WPI: 2001-425873/45.
XX	
P1	New polynucleotide encoding a prostate-specific protein, for
P1	diagnosing, monitoring and treating prostate cancer in a patient and
P1	for use in vaccines .
PS	claim 1; Page 347-348; 54 pp; English.
XX	
CC	The present invention describes polynucleotide sequences (1) which encode
CC	prostate specific proteins (11), (1) and (11) have cytotatic activity;
CC	and can be used in vaccine production and gene therapy; (1); (11);
CC	antibodies to (11), fusion proteins comprising (11); and isolated
CC	T cells prepared using (1) or (11) are used treat cancer in a patient
CC	(1) and the antibodies are also used in the detection of cancer in a
CC	patient. The cancer that is diagnosed or treated is particularly
CC	prostate cancer. (1) and (11) can be used in vaccines. The antibody of
CC	(1) can be used for monitoring the progression of cancer in a patient
CC	(1) and (11) can also be used to improve diagnostic and therapeutic
CC	methods for prostate cancer. They can indicate the level of metastasis
CC	as well as the prostate volume. AAB93457 to AAB93644 and AAM01171 to
CC	AAM01318 represent polynucleotide and amino acid sequences used in the
CC	exemplification of the present invention.
XX	
SO	Sequence 2000 BP; 698 A; 408 C; 480 G; 425 T; 4 other

27	42	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85															

[illegible]

Db	601	gtcccttaacacaaaagatgagatcaggtctgctataaagtcgcatacaattgcacgaatgaaatgaa	640
Gy	661	tattatgttatatt	720
Db	661	tattatgttatatt	720
Gy	721	accactctgacctaagctctatataataataaataatgttgcacaaatgactactcttcttctt	780
Db	721	accactctgacctaagctctatataataataaataatgttgcacaaatgactactcttcttctt	780
Gy	781	tattatgttatatt	840
Db	781	tattatgttatatt	840
Gy	841	ctttatgcataatgcataatgcataatgcataatgcataatgcataatgcataatgcataatgcata	900
Db	841	ctttatgcataatgcataatgcataatgcataatgcataatgcataatgcataatgcataatgcata	900
Gy	901	ctttatgcataatgcataatgcataatgcataatgcataatgcataatgcataatgcataatgcata	960
Db	901	ctttatgcataatgcataatgcataatgcataatgcataatgcataatgcataatgcataatgcata	960
Gy	961	gtcagcctcttacttgcagcaaaatattatgatatctcttgcagcaatgcataatgcataatgcata	1020
Db	961	gtcagcctcttacttgcagcaaaatattatgatatctcttgcagcaatgcataatgcataatgcata	1020
Gy	1021	gtcagcctcttacttgcagcaaaatattatgatatctcttgcagcaatgcataatgcataatgcata	1080
Db	1021	gtcagcctcttacttgcagcaaaatattatgatatctcttgcagcaatgcataatgcataatgcata	1080
Gy	1081	aaagaataaagagatgcataaataatgcataatgcataatgcataatgcataatgcataatgcata	1128
Db	1081	aaagaataaagagatgcataaataatgcataatgcataatgcataatgcataatgcataatgcata	1128
RESULT 10			
1D	AAC81013		
1D	AAC81013 standard, cDNA, 2940 bp		
AC	AAC81013:		
XX	13-FEB-2001 (first entry)		
D1			
XX			
DE	Human B1A41 antigen splice isoform B1A41-9-16 cDNA.		
KM	Human breast tumour-specific antigen; cytosolic; vaccine;		
KM	breast cancer; B1A41; B1A41; B1A41; SS.		
XX	Homo sapiens.		
OS			
XX	W0200061753-A2.		
PM	19-OCT-2000.		
XX			
XX	07-APR-2000; 2000W00009312.		
XX			
PR	09-APR-1999; 90US-0289198.		
XX	28-OCT-1999; 90US-0429255.		
PR	23-MAR-2000; 2003US-0534625.		
XX			
PA	(COR1-) CORIXA CORP.		
PI	Frudakis TN, Smith JM, Reed SG, Mishler LE, Rotter MW, Dillon DC;		
XX	WPI: 2000-528403/50.		
XX	P-PSDB: AAB29639.		
XX			
XX	An isolated polypeptide comprising an immunogenic portion of a breast		
PI	tumour protein used for inhibiting the development of cancer, especially		
PI	breast cancer, and monitoring cancer progression in a patient.		
PS	claim 4; Page 178; 107pp; English.		

XX The Present sequence is given in a specification relating to compositions
CC and methods for the treatment and diagnosis of breast cancer. Nucleotide
CC sequences that are preferentially expressed in breast tumour tissue, and
CC the polypeptides encoded by such nucleotide sequences, are used in
CC compositions and vaccines to inhibit the development of cancer,
CC especially breast cancer. The progression of a cancer may be monitored by
CC carrying out detection of tumour-specific antigens at subsequent time
CC points and comparing the results from the different time points.
CC CC1 and/or CC28 T cells isolated from the cancer patient may be treated
CC with tumour-specific polypeptides, polynucleotides encoding the
CC polypeptides or antigen presenting cells expressing the polypeptides. The
CC cells are then administered to the patient to inhibit development of
CC cancer.
XX
XX Sequence: 2649 bp; 714 A; 392 C; 509 G; 432 T; 0 other;

Query Match	97.78;	Score 1128;	DB 21;	Length 2040;
Best Local Similarity	100.00;	Prod. No. 0;		
Matches 1128;	Conservative	0;	Mismatches	0;
			Indels	0;
			Gaps	0;

[illegible]

[illegible][illegible]

XX AA02781:
 AC
 XX
 DI 14-JUN-2001 (first entry)
 XX
 DE Prostate tumour antigen determined cDNA splice variant of B305D #10.
 XX
 KW Human: prostate tumour antigen; Prostate tumour; therapy; diagnosis;
 XX Prostate cancer; immunogenic; cytostatic; vaccine; ss
 OS Homo sapiens.
 XX
 PN WO200125272-A2.
 PD 12-APR-2001.
 XX
 PE 04-OCT-2000; 2000WO-0527444.
 XX
 PR 04-OCT-1999; 9905-0157455.
 XX
 PA (CORI-) CORIXA CORP.
 PI Xu J, Skelky YAW, Ford SO, Cheever MA;
 XX WPI: 2001-24562/25.
 DR P-PSDB: AA074817.
 XX
 PT Prostate specific protein and its encoding polynucleotide, useful for
 XX the treatment and diagnosis of prostate cancer -
 XX
 PS Claim 50; Page 233; 276pp; English.
 XX
 CC The present invention describes an isolated polypeptide (1) comprising
 CC at least an immunogenic portion of a prostate tumour antigen protein or
 CC its variant, (1) have cytostatic activity and can be used in vaccine
 CC production, (1) prostate tumour antigen polynucleotides, an antigen
 CC presenting cell (Ape-Cell, a dendritic cell) that expresses (1), and a
 CC pharmaceutical composition containing (1) are useful for inhibiting the
 CC development of cancer in a patient. Antibodies specific for prostate
 CC specific proteins and oligonucleotides that hybridise to a
 CC polynucleotide that encodes a prostate specific protein are useful
 CC for detecting the presence or absence of a cancer, especially prostate cancer
 CC AA02422 to AA02872, AA074798 to AA074821 and AA074830 are sequences
 CC used in the exemplification of the present invention.
 CC
 CC Sequence: 2040 BP; 715 A; 392 C; 500 G; 432 T; 0 other;
 CC
 CC Query Match: 97.74; Score 1128; DB 23; Length 2040;
 CC Host Local Similarity: 100.08; Pred. No. 0;
 CC Matches 1128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 CC
 CC 1 at at ggt t t a g g t t g a t t c c c t g a c t c t c t a t a g a a a a g c a t t g a t c 60
 CC 1 at at g g t t a a g g t t a t c a t c a g c t g c c t c t c t a t g a a g a a c a t t t g a t c 60
 CC 61 a a g a c a a t a g g a a a t a a t a a t c c c t t a c t t e r e c t g c g a g a a g a a g a a g 120
 CC 61 a a g a c a a t a g g a a a t a g g a a t g t t g c g g t t g c t c c c c t g c a t g g a g a g a g 120
 CC 121 a a c a a c t t g g c a c t c t g a g a c c a a g a c t c t g a t t g a a g a a c t c a a g a a g 180
 CC 121 a a c a a c t t g g c a c t c t g a g a c c a a g a c t c t g a t t g a a g a a c t c a a g a a g 180
 CC 181 a t g a a c a a t a g t a c c a c t g t t c c c c t g a t g c a g a g a a t g g a a a a c a a g a 240
 CC 181 a t g a a c a a t a g t a c c a c t g t t c c c c t g a t g c a g a g a a t g g a a a a c a a g a 240
 CC 241 g a c a c t t c t g a g a c c a a g a c t c t g a t a t a a a a g a t c a a g a a a a t g g a a g 300
 CC 241 g a c a c t t c t g a g a c c a a g a c t c t g a t a t a a a a g a t c a a g a a a a t g g a a g 300

UY 301 t a t g t t g c c a c t g c t c c c c t g t c c a g g g g a a t g g a a g a a g a a g t t t g a 360
 DB 301 t a t g t t g c c a c t g c t c c c c t g t c c a g g g g a a t g g a a g a a g a a g t t t g a 360
 UY 361 g a a g a t a c a t g a c a a t g c t t a t g g a g c c a a g t a c c a g t c c a t g a a a t a c t a 420
 DB 361 g a a g a t a c a t g a c a a t g c t t a t g g a g c c a a g t a c c a g t c c a t g a a a t a c t a 420
 UY 421 a a c a a t c c a a a g a a t g g a a t g t t g g t a a g t t c c a a a a a g a a t a t a t a t a 480
 DB 421 a a c a a t c c a a a g a a t g g a a t g t t g g t a a g t t c c a a a a a g a a t a t a t a t a 480
 UY 481 c t c a a g a c a c t g a c t g a a c a a g a a g a c a a g a a a a g a a c t g c t c a a t t g g c c 540
 DB 481 c t c a a g a c a c t g a c t g a a c a a g a a g a c a a g a a a a g a a c t g c t c a a t t g g c c 540
 UY 541 t c t g a a t g g a a t g g a a t g g a a t g g a a t g g a a t g g a a t g g a a t g g a a t g g a 600
 DB 541 t c t g a a t g g a a t g g a a t g g a a t g g a a t g g a a t g g a a t g g a a t g g a a t g g a 600
 UY 601 g t c c t t g a 660
 DB 601 g t c c t t g a 660
 UY 661 t a t g t t a a g t t g t a a a a t g g a c t g a t a a a t a t c c a a g t a t a t a a a a t 720
 DB 661 t a t g t t a a g t t g t a a a a t g g a c t g a t a a a t a t c c a a g t a t a t a a a a t 720
 UY 721 a c c a t c c a c t a c c a t a t a t a 780
 DB 721 a c c a t c c a c t a c c a t a t a t a 780
 UY 781 t a t g t t g a t a t g a t c a 840
 DB 781 t a t g t t g a t a t g a t c a 840
 UY 841 c a t a a g a 900
 DB 841 c a t a a g a 900
 UY 901 c t g a a a a t a g a a a a t g c t a t a t a t a t a t a t a t a t a t a t a t a t a t a t a 960
 DB 901 c t g a a a a t a g a a a a t g c t a t a t a t a t a t a t a t a t a t a t a t a t a t a t a 960
 UY 961 g t c a c t t c a c t t g a a a a t a t a t a t a t a t a t a t a t a t a t a t a t a t a t a 1020
 DB 961 g t c a c t t c a c t t g a a a a t a t a t a t a t a t a t a t a t a t a t a t a t a t a t a 1020
 UY 1021 g c a a a a a t a g t a t t c t a t c a t c a a a a t a t a t a t a t a t a t a t a t a t a t 1080
 DB 1021 g c a a a a a t a g t a t t c t a t c a t c a a a a t a t a t a t a t a t a t a t a t a t a t 1080
 UY 1081 a 1128
 DB 1081 a 1128
 RESOUT 15
 AAA06599
 ID AAA06599 standard; cDNA; 2000 BP.
 XX
 AC AAA06599;
 XX
 DI 13 JUN 2000 (first entry)
 XX
 DE Human immunogenic prostate tumour protein cDNA sequence SEQ ID NO: 374.
 XX
 KW Human: prostate cancer; diagnosis; tumour; gene therapy; detection;
 XX Immunogenic; cytostatic; vaccine; ss.
 OS Homo sapiens.
 XX
 PN WO200004149-A2.

[illegible][illegible]

Search completed: March 9, 2004; 05:01:48
Job time: 620H Sec

Sat Mar 9 09:57:21 2002

us-09-699-295-301.rng

Page 16

Software version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

Memo: us-09-699-295-301

March 9, 2002, 09:57:21 - Search Time 78.94 Seconds
(with all updates)
334,942 Million cell updates/sec

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

ALPHABETICS

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

us-09-699-295-301

COMPILED: IBM PC compatible
OPERATING SYSTEM: PC DOS/MS DOS
SOFTWARE: Patent In Process #1.0, Version #1.40
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US 09/622,400
FILING DATE: 12 Dec 1998
CLASSIFICATION:
ALTERNATIVE INFORMATION:
NAME: Mark, David J.
REGISTRATION NUMBER: 41,992
PUBLICATION NUMBER: 2001/24,401/1
PUBLICATION DATE: 2001/06/22/400
TELEPHONE: (206) 682-6041
TELEFAX: (206) 682-6041
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 647 base pairs
TYPE: nucleotide acid
STRANDEDNESS: single
ORIENTATION: forward
GC: 59.411, 200.1

Query Match 1.6K; Score 18; DB 4; Length 3877;
Best Local Similarity: 100.0%; Prod. No. 12;
Matches: 18; Conserved: 0; Mismatches: 0; Indels: 0; Gaps: 0.
DB: 8595 TCAAAATTTTAACTAATA 6612

RESULT 5
US-09-622-676-1
Sequence 1: Application US/09/622,676
Patent No. 6,107,284
GENERAL INFORMATION:
APPLICANT: Etkowicz, Robert Z.
TITLE OF INVENTION: INHIBITORS OF LIPID-DEPENDENT PROTEIN EXPORT
NUMBER OF SEQUENCES: 14
CORRESPONDENT ADDRESS:
ADDRESSEE: Seed and Berry LLP
STREET: 6400 Columbia Court, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPILED: IBM PC compatible
OF PUBLICATION CYCLE: 12 Dec 2001
SOFTWARE: Patent In Process #1.0, Version #1.40
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/622,676
FILING DATE:
CLASSIFICATION:
PUBLICATION DATA:
APPLICATION NUMBER: US 09/622,676
FILING DATE: 12 Dec 1998
ALTERNATIVE INFORMATION:
NAME: Mark, David J.
REGISTRATION NUMBER: 41,992
PUBLICATION NUMBER: 2001/24,401/1
PUBLICATION DATE: 2001/06/22/400
TELEPHONE: (206) 682-6041
TELEFAX: (206) 682-6041
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 647 base pairs
TYPE: nucleotide acid
STRANDEDNESS: single
ORIENTATION: forward
GC: 59.411, 200.1

Query Match 1.6K; Score 18; DB 4; Length 3877;
Best Local Similarity: 100.0%; Prod. No. 12;
Matches: 18; Conserved: 0; Mismatches: 0; Indels: 0; Gaps: 0.
DB: 8595 TCAAAATTTTAACTAATA 6612

RESULT 6
US-09-466-036A-1
Sequence 1: Application US/09/466,036A
Patent No. 6,281,197
GENERAL INFORMATION:
APPLICANT: Etkowicz, Robert Z.
TITLE OF INVENTION: INHIBITORS OF LIPID-DEPENDENT PROTEIN EXPORT
NUMBER OF SEQUENCES: 14
CORRESPONDENT ADDRESS:
ADDRESSEE: Seed and Berry LLP
STREET: 6400 Columbia Court, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPILED: IBM PC compatible
OPERATING SYSTEM: PC DOS/MS DOS
SOFTWARE: Patent In Process #1.0, Version #1.40
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/466,036A
FILING DATE: 17 Dec 2001
CLASSIFICATION: unknown
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 09/621,200
FILING DATE: unknown
ALTERNATIVE INFORMATION:
NAME: Mark, David J.
REGISTRATION NUMBER: 41,992
PUBLICATION NUMBER: 2001/24,401/1
PUBLICATION DATE: 2001/06/22/400
TELEPHONE: (206) 682-6041
TELEFAX: (206) 682-6041
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 4877 base pairs
TYPE: nucleotide acid
STRANDEDNESS: single
ORIENTATION: forward
GC: 59.411, 200.1
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-466-036A-1

Query Match 1.6K; Score 18; DB 4; Length 3877;
Best Local Similarity: 100.0%; Prod. No. 12;
Matches: 18; Conserved: 0; Mismatches: 0; Indels: 0; Gaps: 0.
DB: 8595 TCAAAATTTTAACTAATA 6612

US-09-664-456A-18
Sequence 18: Application US/09/664,456A
Patent No. 6,022,687
GENERAL INFORMATION:
APPLICANT: Iorio, Michelle
APPLICANT: Marchuk, Douglas A.
APPLICANT: Wallisier, Kimberly
TITLE OF INVENTION: DIAGNOSTICS OF AND THERAPY FOR

```

: TITLE OF INVENTION: HEREDITARY HAEMOPHAGIC TELANGIECTASIA
: NUMBER OF SEQUENCES: 42
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Fish & Richardson P.C.
: STREET: 225 Franklin Street
: CITY: Boston
: STATE: MA
: COUNTRY: USA
: ZIP: 02110-2804
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Diskette
: OPERATING SYSTEM: Windows 95
: SOFTWARE: FASTSU for Windows Version 2.0b
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/504,496C
: FILING DATE: 29-NOV-1995
: PRIORITY APPLICATION DATA:
: APPLICATION NUMBER: 08/346,129
: FILING DATE: 29-NOV-1994
: ATTORNEY/AGENT INFORMATION:
: NAME: Fraser, Janis K.
: REGISTRATION NUMBER: 34,819
: REFERENCE/PROXY NUMBER: 06765/000001
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 617/542-5070
: TELEFAX: 617/542-8906
: TELETYPE: 200154
: INFORMATION FOR SEQ ID NO: 18:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 654 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: double
: TOPOLOGY: linear
: MOLECULE TYPE: Genomic DNA
: US-08-564-496C-18

Query Match 1.5%; Score 17; DB 3; Length 654;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 479 tgcctagagagactgac 495
: |||||
Db 108 tgcctagagagactgac 124

RESULT 8
: PCT-US95-15428-18
: Sequence 18, Application PC/TUS9515428
: GENERAL INFORMATION:
: APPLICANT: Letatier, Michelle
: APPLICANT: Marchuk, Douglas A.
: APPLICANT: McAllister, Kimberly
: TITLE OF INVENTION: DIAGNOSIS OF AND THERAPY FOR
: TITLE OF INVENTION: HEREDITARY HAEMOPHAGIC TELANGIECTASIA
: NUMBER OF SEQUENCES: 41
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Fish & Richardson P.C.
: STREET: 225 Franklin Street Suite 300
: CITY: Boston
: STATE: Massachusetts
: COUNTRY: U.S.A.
: ZIP: 02110-2804
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patoutin Release #1.0, Version #1.30B
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: PC/TUS95/15428
: FILING DATE: 29-NOV-1995
: PRIOR APPLICATION DATA:

```

```

: APPLICATION NUMBER: 08/346,129
: FILING DATE: 29-NOV-1994
: ATTORNEY/AGENT INFORMATION:
: NAME: Fraser, Janis K.
: REGISTRATION NUMBER: 34,819
: REFERENCE/PROXY NUMBER: 06765/000001
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 617/542-5070
: TELEFAX: 617/542-8906
: TELETYPE: 200154
: INFORMATION FOR SEQ ID NO: 18:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 656 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: double
: TOPOLOGY: linear
: MOLECULE TYPE: DNA (genomic)
: PCT-US95-15428-18

Query Match 1.5%; Score 17; DB 5; Length 656;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 479 tgcctagagagactgac 495
: |||||
Db 111 tgcctagagagactgac 127

RESULT 9
: US 08 650 129 1/c
: Sequence 1, Application US/08650129
: Patent No. 5747322
: GENERAL INFORMATION:
: APPLICANT: Tsui, Christopher A.
: TITLE OF INVENTION: Recombinant Crab Collagenase
: NUMBER OF SEQUENCES: 6
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Majestic Parsons Siebert & Hsue
: STREET: Four Embarcadero Center, Suite 1450
: CITY: San Francisco
: STATE: CA
: COUNTRY: USA
: ZIP: 94111-4121
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patoutin Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/650,129
: FILING DATE: 09-MAY-1996
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: Siebert, J. Suzanne
: REGISTRATION NUMBER: 28,758
: REFERENCE/PROXY NUMBER: 3500 084050
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (415) 362-5556
: TELEFAX: (415) 362-5418
: INFORMATION FOR SEQ ID NO: 1:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 734 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: cDNA
: US-08-650-129-1

Query Match 1.5%; Score 17; DB 1; Length 734;
Best Local Similarity 100.0%; Pred. No. 35;

```


[illegible]

Search completed: March 9, 2002, 04:15:14
Job time: 00:02:00



Sequence results in 4.5
Copyright (c) 1994 - 2000 Compugen Ltd.

Maximum Search, using SW method

March 9, 2002, 00:41:21 Search time 1719.45 Seconds

(without alignment)
1082.246 Million cell updates/sec

US 09 699 295 301

Postfix

Sequence

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

US 09 699 295 301

Result
No. Score Match Length ID

1	1155	100.0	1155	6	AX106592	Insert 1155
2	1155	100.0	1155	6	AX140883	AX106592 Sequence
3	1141.6	98.0	2000	6	AX106593	AX140883 Sequence
4	1141.6	98.0	2000	6	AX140884	AX106594 Sequence
5	1141.6	98.0	2040	6	AX106594	AX140885 Sequence
6	1141.6	98.0	2040	6	AX140885	AX106598 Sequence
7	1088.6	94.3	1853	6	AX140886	AX106599 Sequence
8	1088.6	94.3	1853	6	AX140887	AX140879 Sequence
9	841	72.8	1852	6	AX141040	AX141040 Sequence
10	829	71.8	1851	6	AX141112	AX141112 Sequence
11	829	71.8	1851	6	AX106595	AX140876 Sequence
12	829	71.8	1851	6	AX140876	AX140876 Sequence
13	829	71.8	2184	6	AX106598	AX140880 Sequence
14	829	71.8	2184	6	AX140880	AX140879 Sequence
15	804.8	69.7	1512	6	AX106587	AX140878 Sequence
16	804.8	69.7	1512	6	AX140878	AX141041 Sequence
17	768	66.5	879	6	AX141041	AX106590 Sequence
18	571.4	49.5	1855	6	AX140881	AX140881 Sequence
19	571.4	49.5	1855	6	AX106591	AX140882 Sequence
20	520	45.0	1059	6	AX140882	AX140882 Sequence
21	518.8	44.9	19968	2	AC018804	AC018804 Sequence
22	480.4	41.6	154077	9	CNS07430	AC018804 Sequence
23	478.8	41.5	155227	2	AC018804	AC018804 Sequence
24	478.8	41.5	155227	2	AC018804	AC018804 Sequence
25	459.6	39.8	172550	2	AC0060814	AC0060814 Sequence
26	456.4	39.5	153077	2	AC020679	AC020679 Sequence
27	456.4	39.3	809555	2	AC026984	AC026984 Sequence
28	451.6	39.1	104785	9	AP001405	AP001405 Sequence
29	451.6	39.1	440000	9	HS21C003	HS21C003 Sequence
30	417.8	36.2	454	6	AK148032	AK148032 Sequence
31	377.8	32.7	64976	2	AC026256	AC026256 Sequence
32	354.4	30.7	1805	9	AK001117	AK001117 Sequence
33	354.4	30.7	5460	9	AB028997	AB028997 Sequence
34	322	27.9	84276	2	AC026641	AC026641 Sequence
35	322	27.9	184109	2	AC048191	AC048191 Sequence
36	322	27.9	217277	2	AC048471	AC048471 Sequence
37	320.4	27.7	167293	2	AC022429	AC022429 Sequence
38	320.4	27.7	177417	2	AC046207	AC046207 Sequence
39	299.4	25.9	3527	9	HS0601761	HS0601761 Sequence
40	278.4	24.1	4458	9	AF269087	AF269087 Sequence
41	274.6	23.8	6673	9	AF269088	AF269088 Sequence
42	215.8	18.7	173957	2	AC091671	AC091671 Sequence
43	206.8	17.9	1388	10	AF294428	AF294428 Sequence
44	196	17.0	1067	9	U78134	U78134 Human mRNA
45	196	17.0	3210	9	AK024286	AK024286 Human cDNA

ALIGNMENTS

RESULT 1
AX106592 1155 bp DNA
Sequence 373 from Patent WO125272.

DEFINITION
AX106592

ACCESSION
AX106592.1 GI:11922263

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

SOURCE

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARY

[illegible][illegible]

Db	361	GGAGCGATGACATGACACAGTGGCTTCCATGAGAGCCAGATACGAGAGTGGGAGAGAAAGATGCG	420
Q7	421	gagcaagctctcagagatcttgcctggcgagagttcaaggtcccaataagagatcctcctcctcctc	480
Db	421	GATTAAGTCTGATATATATATCTGCTGGGCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG	480
Q7	481	ctctggagagagcttgaagctgacacag	540
Db	481	CTCAGAGACACTGACGTGGAGACAG	540
Q7	541	tctctccaaatgggaatccaaagagagatgaactcctgctggagagagagagagagagagagag	600
Db	541	TCTCTCATGTGCAATTTGAT	600
Q7	601	gtcctcttaccag	660
Db	601	GTTCTCTTACACACAAAG	660
Q7	661	tatgagatgagatgttgtgtggagagatggagagagagagagagagagagagagagagagagag	720
Db	661	TGTGTCTTAACTTTCT	720
Q7	721	acgcctctgcacacagcagctatcagctatgagagatgaattatggctcagagagagagagag	780
Db	721	ACGACATCTGACATACAT	780
Q7	781	tatgctgctatataatgaatccaaag	840
Db	781	TATGTCTCTTAT	840
Q7	841	catggagcaaaagacagagatcctggagatlltlaatcaagagagagagagagagagagagag	900
Db	841	CATGACGCAAAAGACAG	900
Q7	901	ctgagatgagatataag	960
Db	901	CTGAT	960
Q7	961	gtcagcctctctacttgaagcaaaatctgaagatctctcacaagatctctcagacagag	1020
Db	961	GTGAGCT	1020
Q7	1021	gccagagagatagatgctgcttctagatgatacatgataatllgcagagctactctctactag	1080
Db	1021	GCCAGAGAGATGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1080
Q7	1081	aaatgaataacagatgctaaataatcctctctgaataacagagagagagagagagagagagag	1138
Db	1081	AAATGAATAACAGATGCTAAATAATCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1138
RESULT	5		
AX106594	AX106594		
DEFINITION	AX106594	2040 bp DNA	PA1
ACCESSION	AX106594	Sequence 375 from Patent WO0125272.	40-APR-2001
VERSION	AX106594.1	CI:13922265	
KEYWORDS			
SOURCE	human.		
ORGANISM	Homo sapiens		
REFERENCE	Enkaryotid Metazoa: Chordata: Primate: Vertebrata: Euteleostomi: Mammalia, Eutheria: Placental: Catarrhini: Hominoidea: Homo. 1 (bases 1 to 2040)		
AUTHORS	Xu, J., Skolky, Y. A., Reed, S. G. and Clever, M. A.		
TITLE	Compositions and methods for therapy and diagnosis of prostate cancer		
JOURNAL	Patent: WO 0125272-A, 375, 12-APR-2001;		
FEATURES	CORLXA CORPORATION (US)		
SOURCE	Location/Qualifiers		
	1..2040		
BASE COUNT	716 a 392 c 500 g 432 t		

	Matches	1104:	Conservative	23:	Mismatches	7:	Indels	5:	Gaps	2:
QY	1	atggtgttggagttgatccatgctgggtgtgctctctctggaagaagacattgtctc	60							
DB	223	ATGGTATTTGAAATTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTT	282							
QY	61	agagagaaatgaggaatggtgtgtgcaattgtctccctctctctgagagagagagag	121							
DB	283	AGGATCAATATGATGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG	342							
QY	121	atgaacgttgggaactctctggaagcagaagactctgtctatgaagaatctgaagag	180							
DB	343	AGCAAGACGCGGCACTCTGGAGAGCAAGCGAGACCTGGATATGAAAGAAATCAAGAGCGAG	402							
QY	181	atgggaatagggtgcgcgcactgtctccctctctgaagagagatggaagagactgtg	240							
DB	403	ATGGGCAATGGTGGGAG	462							
QY	241	gagcgtctctggaagcagaagactctgtctatgaagacactcaagaagaagatggcaag	300							
DB	463	AGAGCTTTCTGTAATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTT	522							
QY	301	tgggtgtgcacatgtctccctgcctgcgaagaggaagcagaagagatgggtgttg	360							
DB	523	TGGTGTGATATTTCTGTTCTGTTCTGTTCTGTTCTGTTCTGTTCTGTTCTGTTCTG	582							
QY	361	ggagatcagagatgacattggtctctggaagcaggtctgagagagagagagagag	420							
DB	583	GGAGATCAGAGATGACATTGATTTATTTATTTATTTATTTATTTATTTATTTATTTAT	642							
QY	421	ggcaagctcagcagagagcgtgctgttgggttaagagcgcgaagaagatctatcttgcg	480							
DB	643	GAGAAATTTCTATGATTTCTATGATTTCTATGATTTCTATGATTTCTATGATTTCTATG	702							
QY	481	ctgagggacactggaacttaacaagaagagacagcaaaagatgaagctgacatgtatgc	540							
DB	703	CTGAGGACACTGGAACCTTAACAAGAAGAGACAGCAAAAGATGAAGCTGACATGTATGC	762							
QY	541	tatggccgatgggaattcaggaattgtaaaatcctgctggagagcagatctcaacttaag	600							
DB	763	TATGGCCGATGGGAATTCAGGAATTGTAAAATCCTGCTGGAGAGCAGATCTCAACTTAAG	822							
QY	601	gtcccttgcacaagaagaagagagcgtctgtatgaaggtctacaaatggcaggaatgaa	660							
DB	823	GTCCTTGCACAAGAAGAAGAGCGTCTGTATGAAGGTCTACAAATGGCAGGAATGAAG	882							
QY	661	tatggttaatgttgttggaaatggcactatccaaattctccagatgaagtgaat	720							
DB	883	TATGTTAATGTGTTGGAAATGGCACTATCCAAATCTCCAGATGAAGTGAAT	942							
QY	721	accacttgcactacgtatctatcaagaagaataaattatggcagaagcctgtcttca	780							
DB	943	ACCACCTTGCACGTATCTATCAAGAAGAATAAATTATATGSCCAAGACACTGCTTCA	1002							
QY	781	tatggtctaatatctgaatccaagaagaagatagcctctacacacacttacttgatga	840							
DB	1003	TATGTTCTAATATGATGATCAAAAACAAACAAAGATGAGCCCTCAACCACTGTTACTTGRTA	1062							
QY	841	catgagctagaagaagacactctggaattctaatcagaagaagaaggaatttaactgc	899							
DB	1063	CATGAGCTAGAAGAAGACACTCTGGAATTCATCAAGAAGAAGAAGGAATTTAACTGC	1122							
QY	900	acttgaatgaataggaaagactgctctctcaatgcttgcgtatgctgttgaagatgata	959							
DB	1123	ACTTGAATGAATAGGAAGACTGCTCTCTCAATGCTTGCCTATGTTGTCATGAGCAAGTAT	1182							
QY	960	attcagact	1019							
DB	1183	ATTCAAGCGCTCTACTTTCAGCAAAATTTGATGATTTCTTCGCAAGCTTCTGCAAG	1248							
QY	1020	ggcagagagatagctcttctctcaatcatcatgataattggcaattactcttgacta	1079							
DB	1249	GCTTGAAGAGATAGCTCTTCTCTCAATCATCATGATATTGGCAATTACTTCTTGACTA	1208							

[illegible]

Accession	Gene	Species	Length (bp)
U00096	16S rRNA	<i>Escherichia coli</i>	1619
U00097	16S rRNA	<i>Salmonella typhimurium</i>	1619
U00098	16S rRNA	<i>Staphylococcus aureus</i>	1619
U00099	16S rRNA	<i>Streptococcus pneumoniae</i>	1619
U00100	16S rRNA	<i>Haemophilus influenzae</i>	1619
U00101	16S rRNA	<i>Mycobacterium tuberculosis</i>	1619
U00102	16S rRNA	<i>Candida albicans</i>	1619
U00103	16S rRNA	<i>Aspergillus fumigatus</i>	1619
U00104	16S rRNA	<i>Geobacillus stearothermophilus</i>	1619
U00105	16S rRNA	<i>Thermophilus thermophilus</i>	1619
U00106	16S rRNA	<i>Halobacterium salinarum</i>	1619
U00107	16S rRNA	<i>Pyrococcus furiosus</i>	1619
U00108	16S rRNA	<i>Methanobacterium thermoautotrophicum</i>	1619
U00109	16S rRNA	<i>Archaeoglobus fulgidus</i>	1619
U00110	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00111	16S rRNA	<i>Thermoplasma volcanium</i>	1619
U00112	16S rRNA	<i>Thermoplasma stammarum</i>	1619
U00113	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00114	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00115	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00116	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00117	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00118	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00119	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00120	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00121	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00122	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00123	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00124	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00125	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00126	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00127	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00128	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00129	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00130	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00131	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00132	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00133	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00134	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00135	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00136	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00137	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00138	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00139	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00140	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00141	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00142	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00143	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00144	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00145	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00146	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00147	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00148	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00149	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00150	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00151	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00152	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00153	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00154	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00155	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00156	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00157	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00158	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00159	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00160	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00161	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00162	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00163	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00164	16S rRNA	<i>Thermoplasma acidophilum</i>	1619
U00165	16S rRNA	<i>Thermoplasma acidophilum</i>	1619

[illegible]

[illegible]

Copyright © 1994 by American Computer Education, Inc.

[illegible][illegible]

K. S. GILL, M. J. MILLER and J. J. HOPKINS/SC

[illegible]

1. The first step is to identify the key components of the system. This involves understanding the hardware, software, and data involved. For example, in a web application, this might include the server, the database, and the user interface.

[illegible]

Journal of Interpersonal Violence 27(10) 1887A

M **1** **2** **3** **4** **5** **6** **7** **8** **9** **10** **11** **12** **13** **14** **15** **16** **17** **18** **19** **20** **21** **22** **23** **24** **25** **26** **27** **28** **29** **30** **31** **32** **33** **34** **35** **36** **37** **38** **39** **40** **41** **42** **43** **44** **45** **46** **47** **48** **49** **50** **51** **52** **53** **54** **55** **56** **57** **58** **59** **60** **61** **62** **63** **64** **65** **66** **67** **68** **69** **70** **71** **72** **73** **74** **75** **76** **77** **78** **79** **80** **81** **82** **83** **84** **85** **86** **87** **88** **89** **90** **91** **92** **93** **94** **95** **96** **97** **98** **99** **100** **101** **102** **103** **104** **105** **106** **107** **108** **109** **110** **111** **112** **113** **114** **115** **116** **117** **118** **119** **120** **121** **122** **123** **124** **125** **126** **127** **128** **129** **130** **131** **132** **133** **134** **135** **136** **137** **138** **139** **140** **141** **142** **143** **144** **145** **146** **147** **148** **149** **150** **151** **152** **153** **154** **155** **156** **157** **158** **159** **160** **161** **162** **163** **164** **165** **166** **167** **168** **169** **170** **171** **172** **173** **174** **175** **176** **177** **178** **179** **180** **181** **182** **183** **184** **185** **186** **187** **188** **189** **190** **191** **192** **193** **194** **195** **196** **197** **198** **199** **200** **201** **202** **203** **204** **205** **206** **207** **208** **209** **210** **211** **212** **213** **214** **215** **216** **217** **218** **219** **220** **221** **222** **223** **224** **225** **226** **227** **228** **229** **230** **231** **232** **233** **234** **235** **236** **237** **238** **239** **240** **241** **242** **243** **244** **245** **246** **247** **248** **249** **250** **251** **252** **253** **254** **255** **256** **257** **258** **259** **260** **261** **262** **263** **264** **265** **266** **267** **268** **269** **270** **271** **272** **273** **274** **275** **276** **277** **278** **279** **280** **281** **282** **283** **284** **285** **286** **287** **288** **289** **290** **291** **292** **293** **294** **295** **296** **297** **298** **299** **300** **301** **302** **303** **304** **305** **306** **307** **308** **309** **310** **311** **312** **313** **314** **315** **316** **317** **318** **319** **320** **321** **322** **323** **324** **325** **326** **327** **328** **329** **330** **331** **332** **333** **334** **335** **336** **337** **338** **339** **340** **341** **342** **343** **344** **345** **346** **347** **348** **349** **350** **351** **352** **353** **354** **355** **356** **357** **358** **359** **360** **361** **362** **363** **364** **365** **366** **367** **368** **369** **370** **371** **372** **373** **374** **375** **376** **377** **378** **379** **380** **381** **382** **383** **384** **385** **386** **387** **388** **389** **390** **391** **392** **393** **394** **395** **396** **397** **398** **399** **400** **401** **402** **403** **404** **405** **406** **407** **408** **409** **410** **411** **412** **413** **414** **415** **416** **417** **418** **419** **420** **421** **422** **423** **424** **425** **426** **427** **428** **429** **430** **431** **432** **433** **434** **435** **436** **437** **438** **439** **440** **441** **442** **443** **444** **445** **446** **447** **448** **449** **450** **451** **452** **453** **454** **455** **456** **457** **458** **459** **460** **461** **462** **463** **464** **465** **466**

Maximum Likelihood Estimation

1. $\frac{1}{2} \times \frac{1}{2} = \frac{1}{4}$
 2. $\frac{1}{2} \times \frac{1}{4} = \frac{1}{8}$
 3. $\frac{1}{4} \times \frac{1}{4} = \frac{1}{16}$
 4. $\frac{1}{4} \times \frac{1}{8} = \frac{1}{32}$
 5. $\frac{1}{8} \times \frac{1}{8} = \frac{1}{64}$
 6. $\frac{1}{8} \times \frac{1}{16} = \frac{1}{128}$
 7. $\frac{1}{16} \times \frac{1}{16} = \frac{1}{256}$
 8. $\frac{1}{16} \times \frac{1}{32} = \frac{1}{512}$
 9. $\frac{1}{32} \times \frac{1}{32} = \frac{1}{1024}$
 10. $\frac{1}{32} \times \frac{1}{64} = \frac{1}{2048}$
 11. $\frac{1}{64} \times \frac{1}{64} = \frac{1}{4096}$
 12. $\frac{1}{64} \times \frac{1}{128} = \frac{1}{8192}$
 13. $\frac{1}{128} \times \frac{1}{128} = \frac{1}{16384}$
 14. $\frac{1}{128} \times \frac{1}{256} = \frac{1}{32768}$
 15. $\frac{1}{256} \times \frac{1}{256} = \frac{1}{65536}$
 16. $\frac{1}{256} \times \frac{1}{512} = \frac{1}{131072}$
 17. $\frac{1}{512} \times \frac{1}{512} = \frac{1}{262144}$
 18. $\frac{1}{512} \times \frac{1}{1024} = \frac{1}{524288}$
 19. $\frac{1}{1024} \times \frac{1}{1024} = \frac{1}{1048576}$
 20. $\frac{1}{1024} \times \frac{1}{2048} = \frac{1}{2097152}$
 21. $\frac{1}{2048} \times \frac{1}{2048} = \frac{1}{4194304}$
 22. $\frac{1}{2048} \times \frac{1}{4096} = \frac{1}{8388608}$
 23. $\frac{1}{4096} \times \frac{1}{4096} = \frac{1}{16777216}$
 24. $\frac{1}{4096} \times \frac{1}{8192} = \frac{1}{33554432}$
 25. $\frac{1}{8192} \times \frac{1}{8192} = \frac{1}{67108864}$
 26. $\frac{1}{8192} \times \frac{1}{16384} = \frac{1}{134217728}$
 27. $\frac{1}{16384} \times \frac{1}{16384} = \frac{1}{268435456}$
 28. $\frac{1}{16384} \times \frac{1}{32768} = \frac{1}{536870912}$
 29. $\frac{1}{32768} \times \frac{1}{32768} = \frac{1}{1073741824}$
 30. $\frac{1}{32768} \times \frac{1}{65536} = \frac{1}{2147483648}$
 31. $\frac{1}{65536} \times \frac{1}{65536} = \frac{1}{4294967296}$
 32. $\frac{1}{65536} \times \frac{1}{131072} = \frac{1}{8589934592}$
 33. $\frac{1}{131072} \times \frac{1}{131072} = \frac{1}{17179869184}$
 34. $\frac{1}{131072} \times \frac{1}{262144} = \frac{1}{34359738368}$
 35. $\frac{1}{262144} \times \frac{1}{262144} = \frac{1}{68719476736}$
 36. $\frac{1}{262144} \times \frac{1}{524288} = \frac{1}{137438953472}$
 37. $\frac{1}{524288} \times \frac{1}{524288} = \frac{1}{274877906944}$
 38. $\frac{1}{524288} \times \frac{1}{1048576} = \frac{1}{549755813888}$
 39. $\frac{1}{1048576} \times \frac{1}{1048576} = \frac{1}{1099511627776}$
 40. $\frac{1}{1048576} \times \frac{1}{2097152} = \frac{1}{2199023255552}$
 41. $\frac{1}{2097152} \times \frac{1}{2097152} = \frac{1}{4398046511104}$
 42. $\frac{1}{2097152} \times \frac{1}{4194304} = \frac{1}{8796093022208}$
 43. $\frac{1}{4194304} \times \frac{1}{4194304} = \frac{1}{17592186044416}$
 44. $\frac{1}{4194304} \times \frac{1}{8388608} = \frac{1}{35184372088832}$
 45. $\frac{1}{8388608} \times \frac{1}{8388608} = \frac{1}{70368744177664}$
 46. $\frac{1}{8388608} \times \frac{1}{16777216} = \frac{1}{140737488355328}$
 47. $\frac{1}{16777216} \times \frac{1}{16777216} = \frac{1}{281474976710656}$
 48. $\frac{1}{16777216} \times \frac{1}{33554432} = \frac{1}{562949953421312}$
 49. $\frac{1}{33554432} \times \frac{1}{33554432} = \frac{1}{1125899906842624}$
 50. $\frac{1}{33554432} \times \frac{1}{67108864} = \frac{1}{2251799813685248}$
 51. $\frac{1}{67108864} \times \frac{1}{67108864} = \frac{1}{4503599627370496}$
 52. $\frac{1}{67108864} \times \frac{1}{134217728} = \frac{1}{9007199254740992}$
 53. $\frac{1}{134217728} \times \frac{1}{134217728} = \frac{1}{18014398509481984}$
 54. $\frac{1}{134217728} \times \frac{1}{268435456} = \frac{1}{36028797018963968}$
 55. $\frac{1}{268435456} \times \frac{1}{268435456} = \frac{1}{72057594037927936}$
 56. $\frac{1}{268435456} \times \frac{1}{536870912} = \frac{1}{144115188075855872}$
 57. $\frac{1}{536870912} \times \frac{1}{536870912} = \frac{1}{288230376151711744}$
 58. $\frac{1}{536870912} \times \frac{1}{1073741824} = \frac{1}{576460752303423488}$
 59. $\frac{1}{1073741824} \times \frac{1}{1073741824} = \frac{1}{1152921504606846976}$
 60. $\frac{1}{1073741824} \times \frac{1}{2147483648} = \frac{1}{2305843009213693952}$
 61. $\frac{1}{2147483648} \times \frac{1}{2147483648} = \frac{1}{4611686018427387904}$
 62. $\frac{1}{2147483648} \times \frac{1}{4294967296} = \frac{1}{9223372036854775808}$
 63. $\frac{1}{4294967296} \times \frac{1}{4294967296} = \frac{1}{18446744073709551616}$
 64. $\frac{1}{4294967296} \times \frac{1}{8589934592} = \frac{1}{36893488147419103232}$
 65. $\frac{1}{8589934592} \times \frac{1}{8589934592} = \frac{1}{73786976294838206464}$
 66. $\frac{1}{8589934592} \times \frac{1}{16777216} = \frac{1}{147573952589676412928}$
 67. $\frac{1}{16777216} \times \frac{1}{16777216} = \frac{1}{295147905179352825856}$
 68. $\frac{1}{16777216} \times \frac{1}{33554432} = \frac{1}{590295810358705651712}$
 69. $\frac{1}{33554432} \times \frac{1}{33554432} = \frac{1}{1180591620717411303424}$
 70. $\frac{1}{33554432} \times \frac{1}{67108864} = \frac{1}{2361183241434822606848}$
 71. $\frac{1}{67108864} \times \frac{1}{67108864} = \frac{1}{4722366482869645213696}$
 72. $\frac{1}{67108864} \times \frac{1}{134217728} = \frac{1}{9444732965739290427392}$
 73. $\frac{1}{134217728} \times \frac{1}{$

Figure 1. Schematic representation of the experimental design. The subjects were divided into two groups: the control group (CG) and the experimental group (EG). The CG was divided into two subgroups: the control group (CG) and the control group (CG). The EG was divided into two subgroups: the experimental group (EG) and the experimental group (EG). The subjects were divided into two groups: the control group (CG) and the experimental group (EG). The CG was divided into two subgroups: the control group (CG) and the control group (CG). The EG was divided into two subgroups: the experimental group (EG) and the experimental group (EG).

項目	単位	数値
1. 総人口	人	1,234,567
2. 男性人口	人	612,345
3. 女性人口	人	622,222
4. 総世帯数	世帯	234,567
5. 男性世帯数	世帯	112,345
6. 女性世帯数	世帯	122,222
7. 総就業人口	人	567,890
8. 男性就業人口	人	289,012
9. 女性就業人口	人	278,878
10. 総所得	円	123,456,789
11. 男性所得	円	61,234,567
12. 女性所得	円	62,222,222
13. 総消費	円	98,765,432
14. 男性消費	円	49,876,543
15. 女性消費	円	48,888,889
16. 総貯蓄	円	24,691,357
17. 男性貯蓄	円	12,345,678
18. 女性貯蓄	円	12,345,679
19. 総投資	円	15,789,012
20. 男性投資	円	7,890,123
21. 女性投資	円	7,898,889
22. 総貯蓄率	%	20.0
23. 男性貯蓄率	%	21.0
24. 女性貯蓄率	%	19.0
25. 総投資率	%	12.8
26. 男性投資率	%	13.5
27. 女性投資率	%	12.5
28. 総消費率	%	80.0
29. 男性消費率	%	79.0
30. 女性消費率	%	81.0
31. 総所得倍率	倍	1.5
32. 男性所得倍率	倍	1.6
33. 女性所得倍率	倍	1.4
34. 総消費倍率	倍	1.2
35. 男性消費倍率	倍	1.3
36. 女性消費倍率	倍	1.1
37. 総貯蓄率	%	20.0
38. 男性貯蓄率	%	21.0
39. 女性貯蓄率	%	19.0
40. 総投資率	%	12.8
41. 男性投資率	%	13.5
42. 女性投資率	%	12.5
43. 総消費率	%	80.0
44. 男性消費率	%	79.0
45. 女性消費率	%	81.0
46. 総所得倍率	倍	1.5
47. 男性所得倍率	倍	1.6
48. 女性所得倍率	倍	1.4
49. 総消費倍率	倍	1.2
50. 男性消費倍率	倍	1.3
51. 女性消費倍率	倍	1.1

Figure	Figure Description	Figure Legend
Figure 1	Flowchart of the study design. The study was a prospective cohort study. It started with 1000 participants who were followed up for 10 years. During this time, 200 participants were lost to follow-up. At the end of the study, 800 participants remained. Of these, 400 were in the intervention group and 400 were in the control group. The intervention group received a new drug, and the control group received a placebo. The primary outcome was the number of participants who died during the study.	Figure 1: Flowchart of the study design.
Figure 2	Bar chart showing the number of participants who died in the intervention group and the control group. The intervention group had 100 deaths, and the control group had 150 deaths.	Figure 2: Bar chart showing the number of participants who died in the intervention group and the control group.
Figure 3	Line graph showing the survival probability over time for the intervention group and the control group. The intervention group has a higher survival probability than the control group throughout the study.	Figure 3: Line graph showing the survival probability over time for the intervention group and the control group.
Figure 4	Forest plot showing the hazard ratio for the intervention group compared to the control group. The hazard ratio is 0.67, with a 95% confidence interval of 0.50 to 0.90.	Figure 4: Forest plot showing the hazard ratio for the intervention group compared to the control group.

[illegible]
$$\begin{aligned} \partial_1 &= \partial_1 \mathbb{R}^n \times \mathbb{R}^n \times \mathbb{R}^n \\ \partial_2 &= \partial_2 \mathbb{R}^n \times \mathbb{R}^n \times \mathbb{R}^n \\ \partial_3 &= \partial_3 \mathbb{R}^n \times \mathbb{R}^n \times \mathbb{R}^n \end{aligned}$$
[illegible]

1. $\frac{1}{2}$ 2. $\frac{1}{3}$ 3. $\frac{1}{4}$ 4. $\frac{1}{5}$ 5. $\frac{1}{6}$ 6. $\frac{1}{7}$ 7. $\frac{1}{8}$ 8. $\frac{1}{9}$ 9. $\frac{1}{10}$ 10. $\frac{1}{11}$ 11. $\frac{1}{12}$ 12. $\frac{1}{13}$ 13. $\frac{1}{14}$ 14. $\frac{1}{15}$ 15. $\frac{1}{16}$ 16. $\frac{1}{17}$ 17. $\frac{1}{18}$ 18. $\frac{1}{19}$ 19. $\frac{1}{20}$ 20. $\frac{1}{21}$ 21. $\frac{1}{22}$ 22. $\frac{1}{23}$ 23. $\frac{1}{24}$ 24. $\frac{1}{25}$ 25. $\frac{1}{26}$ 26. $\frac{1}{27}$ 27. $\frac{1}{28}$ 28. $\frac{1}{29}$ 29. $\frac{1}{30}$ 30. $\frac{1}{31}$ 31. $\frac{1}{32}$ 32. $\frac{1}{33}$ 33. $\frac{1}{34}$ 34. $\frac{1}{35}$ 35. $\frac{1}{36}$ 36. $\frac{1}{37}$ 37. $\frac{1}{38}$ 38. $\frac{1}{39}$ 39. $\frac{1}{40}$ 40. $\frac{1}{41}$ 41. $\frac{1}{42}$ 42. $\frac{1}{43}$ 43. $\frac{1}{44}$ 44. $\frac{1}{45}$ 45. $\frac{1}{46}$ 46. $\frac{1}{47}$ 47. $\frac{1}{48}$ 48. $\frac{1}{49}$ 49. $\frac{1}{50}$ 50. $\frac{1}{51}$ 51. $\frac{1}{52}$ 52. $\frac{1}{53}$ 53. $\frac{1}{54}$ 54. $\frac{1}{55}$ 55. $\frac{1}{56}$ 56. $\frac{1}{57}$ 57. $\frac{1}{58}$ 58. $\frac{1}{59}$ 59. $\frac{1}{60}$ 60. $\frac{1}{61}$ 61. $\frac{1}{62}$ 62. $\frac{1}{63}$ 63. $\frac{1}{64}$ 64. $\frac{1}{65}$ 65. $\frac{1}{66}$ 66. $\frac{1}{67}$ 67. $\frac{1}{68}$ 68. $\frac{1}{69}$ 69. $\frac{1}{70}$ 70. $\frac{1}{71}$ 71. $\frac{1}{72}$ 72. $\frac{1}{73}$ 73. $\frac{1}{74}$ 74. $\frac{1}{75}$ 75. $\frac{1}{76}$ 76. $\frac{1}{77}$ 77. $\frac{1}{78}$ 78. $\frac{1}{79}$ 79. $\frac{1}{80}$ 80. $\frac{1}{81}$ 81. $\frac{1}{82}$ 82. $\frac{1}{83}$ 83. $\frac{1}{84}$ 84. $\frac{1}{85}$ 85. $\frac{1}{86}$ 86. $\frac{1}{87}$ 87. $\frac{1}{88}$ 88. $\frac{1}{89}$ 89. $\frac{1}{90}$ 90. $\frac{1}{91}$ 91. $\frac{1}{92}$ 92. $\frac{1}{93}$ 93. $\frac{1}{94}$ 94. $\frac{1}{95}$ 95. $\frac{1}{96}$ 96. $\frac{1}{97}$ 97. $\frac{1}{98}$ 98. $\frac{1}{99}$ 99. $\frac{1}{100}$ 100. $\frac{1}{101}$ 101. $\frac{1}{102}$ 102. $\frac{1}{103}$ 103. $\frac{1}{104}$ 104. $\frac{1}{105}$ 105. $\frac{1}{106}$ 106. $\frac{1}{107}$ 107. $\frac{1}{108}$ 108. $\frac{1}{109}$ 109. $\frac{1}{110}$ 110. $\frac{1}{111}$ 111. $\frac{1}{112}$ 112. $\frac{1}{113}$ 113. $\frac{1}{114}$ 114. $\frac{1}{115}$ 115. $\frac{1}{116}$ 116. $\frac{1}{117}$ 117. $\frac{1}{118}$ 118. $\frac{1}{119}$ 119. $\frac{1}{120}$ 120. $\frac{1}{121}$ 121. $\frac{1}{122}$ 122. $\frac{1}{123}$ 123. $\frac{1}{124}$ 124. $\frac{1}{125}$ 125. $\frac{1}{126}$ 126. $\frac{1}{127}$ 127. $\frac{1}{128}$ 128. $\frac{1}{129}$ 129. $\frac{1}{130}$ 130. $\frac{1}{131}$ 131. $\frac{1}{132}$ 132. $\frac{1}{133}$ 133. $\frac{1}{134}$ 134. $\frac{1}{135}$ 135. $\frac{1}{136}$ 136. $\frac{1}{137}$ 137. $\frac{1}{138}$ 138. $\frac{1}{139}$ 139. $\frac{1}{140}$ 140. $\frac{1}{141}$ 141. $\frac{1}{142}$ 142. $\frac{1}{143}$ 143. $\frac{1}{144}$ 144. $\frac{1}{145}$ 145. $\frac{1}{146}$ 146. $\frac{1}{147}$ 147. $\frac{1}{148}$ 148. $\frac{1}{149}$ 149. $\frac{1}{150}$ 150. $\frac{1}{151}$ 151. $\frac{1}{152}$ 152. $\frac{1}{153}$ 153. $\frac{1}{154}$ 154. $\frac{1}{155}$ 155. $\frac{1}{156}$ 156. $\frac{1}{157}$ 157. $\frac{1}{158}$ 158. $\frac{1}{159}$ 159. $\frac{1}{160}$ 160. $\frac{1}{161}$ 161. $\frac{1}{162}$ 162. $\frac{1}{163}$ 163. $\frac{1}{164}$ 164. $\frac{1}{165}$ 165. $\frac{1}{166}$ 166. $\frac{1}{167}$ 167. $\frac{1}{168}$ 168. $\frac{1}{169}$ 169. $\frac{1}{170}$ 170. $\frac{1}{171}$ 171. $\frac{1}{172}$ 172. $\frac{1}{173}$ 173. $\frac{1}{174}$ 174. $\frac{1}{175}$ 175. $\frac{1}{176}$ 176. $\frac{1}{177}$ 177. $\frac{1}{178}$ 178. $\frac{1}{179}$ 179. $\frac{1}{180}$ 180. $\frac{1}{181}$ 181. $\frac{1}{182}$ 182. $\frac{1}{183}$ 183. $\frac{1}{184}$ 184. $\frac{1}{185}$ 185. $\frac{1}{186}$ 186. $\frac{1}{187}$ 187. $\frac{1}{188}$ 188. $\frac{1}{189}$ 189. $\frac{1}{190}$ 190. $\frac{1}{191}$ 191. $\frac{1}{192}$ 192. $\frac{1}{193}$ 193. $\frac{1}{194}$ 194. $\frac{1}{195}$ 195. $\frac{1}{196}$ 196. $\frac{1}{197}$ 197. $\frac{1}{198}$ 198. $\frac{1}{199}$ 199. $\frac{1}{200}$ 200. $\frac{1}{201}$ 201. $\frac{1}{202}$ 202. $\frac{1}{203}$ 203. $\frac{1}{204}$ 204. $\frac{1}{205}$ 205. $\frac{1}{206}$ 206. $\frac{1}{207}$ 207. $\frac{1}{208}$ 208. $\frac{1}{209}$ 209. $\frac{1}{210}$ 210. $\frac{1}{211}$ 211. $\frac{1}{212}$ 212. $\frac{1}{213}$ 213. $\frac{1}{214}$ 214. $\frac{1}{215}$ 215. $\frac{1}{216}$ 216. $\frac{1}{217}$ 217. $\frac{1}{218}$ 218. $\frac{1}{219}$ 219. $\frac{1}{220}$ 220. $\frac{1}{221}$ 221. $\frac{1}{222}$ 222. $\frac{1}{223}$ 223. $\frac{1}{224}$ 224. $\frac{1}{225}$ 225. $\frac{1}{226}$ 226. $\frac{1}{227}$ 227. $\frac{1}{228}$ 228. $\frac{1}{229}$ 229. $\frac{1}{230}$ 230. $\frac{1}{231}$ 231. $\frac{1}{232}$ 232. $\frac{1}{233}$ 233. $\frac{1}{234}$ 234. $\frac{1}{235}$ 235. $\frac{1}{236}$ 236. $\frac{1}{237}$ 237. $\frac{1}{238}$ 238. $\frac{1}{239}$ 239. $\frac{1}{240}$ 240

[illegible]

17 : **000985** | **100** : ★

[illegible]

$\frac{1}{2} \left(\frac{1}{2} \right) = \frac{1}{4}$

Proof. No, as the number of results predicted by chance to

and is derived by dividing the total score of 181 by 10.

SUMMARY

$$\frac{1}{\lambda} \|\mathbf{A} \cdot \mathbf{A}^T\|(\mathbf{C})$$
[illegible][illegible][illegible][illegible][illegible][illegible][illegible]

ACCESSION H55862
 VERSION H55862.1 GI:2610196
 KEYWORDS GSS.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo
 1 (bases 1 to 503)
 REFERENCE Adams, M.D., Kousley, S.D., Field, C.F., Bass, S., Liber, K., Golden
 K., Berry, K., Graner, D., Sub, R., Wible, C., Shizuya, H., Simon, M.
 and Venter, J.C.
 Use of a random BAC end sequence database for sequence ready map
 building
 TITLE Unpublished (1997)
 JOURNAL Other GSS: CIT-HSP-2005F16 TP
 COMMENT Contact: Mark Adams
 Department of Eukaryotic Genomics
 The Institute for Genomic Research
 9712 Medical Center Dr., Rockville, MD 20850, USA
 Tel: 301 838 0200
 Fax: 301 838 0258
 Email: madams@tigr.org
 Clones are available from Research Genetics (info@resgen.com). BAC
 end search page:
<http://www.tigr.org/tdb/euk-arch/euk-arch-search.html>
 Seq primer: M13-21
 Class: BAC ends.
 FEATURES
 SOURCE Location/Qualifiers
 1..503
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /db_xref="taxon:9606"
 /clone="2005F16"
 /clone_lib="CIT-HSP"
 /sex="Male"
 /cell_type="Sperm"
 /note="Vector: pGEM-PAC1, Site_1, HindIII, Site_2,
 HindIII"
 BASE COUNT 152 a 116 c 87 g 148 t
 ORIGIN
 Query Match 3.5% Score 40; LR 13; Length 503;
 Best Local Similarity 100.0%; Prod No 1 to 0;
 Matches 40; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 07 1087 aacagatgctaaatgctcttctgaaatgacacatctga 1126
 ||||||||||||||||||||||||||||||||||||||||
 db 502 AACAGATGCTAAATAATCTCTGAAATACGACATCCAG 463
 RESULT 12
 ACQ00910 1011 bp DNA GSS 10-NOV-1999
 LOCUS H5_2055_B1.R05.17G CIT Approved Human Genomic Sperm Library D Homo
 sapiens genomic clone plate 2055 Col-9 Row-D, DNA sequence.
 ACCESSION ACQ00910
 VERSION ACQ00910.1 GI:6357012
 KEYWORDS GSS.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
 1 (bases 1 to 1011)
 REFERENCE Mahairas, G.G., Wallace, J.C., Smith, K., Swartzell, S., Holzman, T.,
 Kellar, A., Shaker, R., Furlong, J., Young, J., Zhao, S., Adams, M.D. and
 Hood, L.
 TITLE Sequence-tagged connectors: A sequence approach to mapping and
 scanning the human genome
 JOURNAL Proc. Natl. Acad. Sci. U. S. A 96 (17), 9730-9744 (1999)
 MEDLINE 99480589
 COMMENT Contact: Mahairas GG, Wallace JC, Hood L
 High Throughput Sequencing Center

University of Washington
 401 Queen Anne Avenue North, Seattle, WA 98109, USA
 Tel: (206) 616-3618
 Fax: (206) 616-3887
 Email: jwallace@u.washington.edu
 Clones may be purchased from Research Genetics (info@resgen.com).
 BAC end Web Server: <http://www.hisc.washington.edu>
 Plate: 2055 row: D column: 9
 Seq primer: 77
 Class: BAC ends
 High quality sequence stop: 1011.
 FEATURES
 SOURCE Location/Qualifiers
 1..1011
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="plate:2055 Col-9 Row-D"
 /clone_lib="CIT Approved Human Genomic Sperm Library D"
 /sex="Male"
 /note="Organ: Sperm; Vector: pGEM-PAC1; BAC clones in
 E-Coli DH10B"
 BASE COUNT 216 a 214 c 143 g 438 t
 ORIGIN
 Query Match 3.4% Score 39; DB 13; Length 1011;
 Best Local Similarity 100.0%; Prod. No. 3,66-09;
 Matches 39; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 07 1054 gtaattgccttacttctgactgaaagaaagaaag 1092
 ||||||||||||||||||||||||||||||||||||||||
 db 207 CTATTCGCATTCCTTCCTGAAATACGACATCCAG 245
 RESULT 13
 ACQ247090 458 bp DNA GSS 07-OCT-1998
 LOCUS H5_2055_B1.R04.17 CIT Approved Human Genomic Sperm Library D Homo
 sapiens genomic clone plate-2055 Col-7 Row-D, DNA sequence.
 ACCESSION ACQ247090
 VERSION ACQ247090.1 GI:1697272
 KEYWORDS GSS.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
 1 (bases 1 to 458)
 REFERENCE Mahairas, G.G., Wallace, J.C., Smith, K., Swartzell, S., Holzman, T.,
 Kellar, A., Shaker, R., Furlong, J., Young, J., Zhao, S., Adams, M.D. and
 Hood, L.
 TITLE Sequence-tagged connectors: A sequence approach to mapping and
 scanning the human genome
 JOURNAL Proc. Natl. Acad. Sci. U. S. A 96 (17), 9730-9744 (1999)
 MEDLINE 99480589
 COMMENT Contact: Mahairas GG, Wallace JC, Hood L
 High Throughput Sequencing Center
 University of Washington
 401 Queen Anne Avenue North, Seattle, WA 98109, USA
 Tel: (206) 616-3618
 Fax: (206) 616-3887
 Email: jwallace@u.washington.edu
 Sequence Tagged Connector
 Plate: 2055 row: D column: 7
 Class: BAC ends
 High quality sequence stop: 458.
 FEATURES
 SOURCE Location/Qualifiers
 1..458
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="plate-2055 Col-7 Row-D"
 /clone_lib="CIT Approved Human Genomic Sperm Library D"
 /sex="Male"
 /note="Organ: Sperm; Vector: pGEM-PAC1; BAC clones in
 E-Coli DH10B"

PAVE 2001	11.00	122.00	68.00	15.80
PAVE 2001	11.00	122.00	68.00	15.80

2007, M. 100; Scott, 1994; 1995; 1996; 1997; 1998; 1999; 2000; 2001; 2002; 2003; 2004; 2005; 2006; 2007; 2008; 2009; 2010; 2011; 2012; 2013; 2014; 2015; 2016; 2017; 2018; 2019; 2020; 2021; 2022; 2023; 2024; 2025; 2026; 2027; 2028; 2029; 2030; 2031; 2032; 2033; 2034; 2035; 2036; 2037; 2038; 2039; 2040; 2041; 2042; 2043; 2044; 2045; 2046; 2047; 2048; 2049; 2050; 2051; 2052; 2053; 2054; 2055; 2056; 2057; 2058; 2059; 2060; 2061; 2062; 2063; 2064; 2065; 2066; 2067; 2068; 2069; 2070; 2071; 2072; 2073; 2074; 2075; 2076; 2077; 2078; 2079; 2080; 2081; 2082; 2083; 2084; 2085; 2086; 2087; 2088; 2089; 2090; 2091; 2092; 2093; 2094; 2095; 2096; 2097; 2098; 2099; 2100; 2101; 2102; 2103; 2104; 2105; 2106; 2107; 2108; 2109; 2110; 2111; 2112; 2113; 2114; 2115; 2116; 2117; 2118; 2119; 2120; 2121; 2122; 2123; 2124; 2125; 2126; 2127; 2128; 2129; 2130; 2131; 2132; 2133; 2134; 2135; 2136; 2137; 2138; 2139; 2140; 2141; 2142; 2143; 2144; 2145; 2146; 2147; 2148; 2149; 2150; 2151; 2152; 2153; 2154; 2155; 2156; 2157; 2158; 2159; 2160; 2161; 2162; 2163; 2164; 2165; 2166; 2167; 2168; 2169; 2170; 2171; 2172; 2173; 2174; 2175; 2176; 2177; 2178; 2179; 2180; 2181; 2182; 2183; 2184; 2185; 2186; 2187; 2188; 2189; 2190; 2191; 2192; 2193; 2194; 2195; 2196; 2197; 2198; 2199; 2200; 2201; 2202; 2203; 2204; 2205; 2206; 2207; 2208; 2209; 2210; 2211; 2212; 2213; 2214; 2215; 2216; 2217; 2218; 2219; 2220; 2221; 2222; 2223; 2224; 2225; 2226; 2227; 2228; 2229; 2230; 2231; 2232; 2233; 2234; 2235; 2236; 2237; 2238; 2239; 2240; 2241; 2242; 2243; 2244; 2245; 2246; 2247; 2248; 2249; 2250; 2251; 2252; 2253; 2254; 2255; 2256; 2257; 2258; 2259; 2260; 2261; 2262; 2263; 2264; 2265; 2266; 2267; 2268; 2269; 2270; 2271; 2272; 2273; 2274; 2275; 2276; 2277; 2278; 2279; 2280; 2281; 2282; 2283; 2284; 2285; 2286; 2287; 2288; 2289; 2290; 2291; 2292; 2293; 2294; 2295; 2296; 2297; 2298; 2299; 2300; 2301; 2302; 2303; 2304; 2305; 2306; 2307; 2308; 2309; 2310; 2311; 2312; 2313; 2314; 2315; 2316; 2317; 2318; 2319; 2320; 2321; 2322; 2323; 2324; 2325; 2326; 2327; 2328; 2329; 2330; 2331; 2332; 2333; 2334; 2335; 2336; 2337; 2338; 2339; 2340; 2341; 2342; 2343; 2344; 2345; 2346; 2347; 2348; 2349; 2350; 2351; 2352; 2353; 2354; 2355; 2356; 2357; 2358; 2359; 2360; 2361; 2362; 2363; 2364; 2365; 2366; 2367; 2368; 2369; 2370; 2371; 2372; 2373; 2374; 2375; 2376; 2377; 2378; 2379; 2380; 2381; 2382; 2383; 2384; 2385; 2386; 2387; 2388; 2389; 2390; 2391; 2392; 2393; 2394; 2395; 2396; 2397; 2398; 2399; 2400; 2401; 2402; 2403; 2404; 2405; 2406; 2407; 2408; 2409; 2410; 2411; 2412; 2413; 2414; 2415; 2416; 2417; 2418; 2419; 2420; 2421; 2422; 2423; 2424; 2425; 2426; 2427; 2428; 2429; 2430; 2431; 2432; 2433; 2434; 2435; 2436; 2437; 2438; 2439; 2440; 2441; 2442; 2443; 2444; 2445; 2446; 2447; 2448; 2449; 2450; 2451; 2452; 2453; 2454; 2455; 2456; 2457; 2458; 2459; 2460; 2461; 2462; 2463; 2464; 2465; 2466; 2467; 2468; 2469; 2470; 2471; 2472; 2473; 2474; 2475; 2476; 2477; 2478; 2479; 2480; 2481; 2482; 2483; 2484; 2485; 2486; 2487; 2488; 2489; 2490; 2491; 2492; 2493; 2494; 2495; 2496; 2497; 2498; 2499; 2500; 2501; 2502; 2503; 2504; 2505; 2506; 2507; 2508; 2509; 2510; 2511; 2512; 2513; 2514; 2515; 2516; 2517; 2518; 2519; 2520; 2521; 2522; 2523; 2524; 2525; 2526; 2527; 2528; 2529; 2530; 2531; 2532; 2533; 2534; 2535; 2536; 2537; 2538; 2539; 2540; 2541; 2542; 2543; 2544; 2545; 2546; 2547; 2548; 2549; 2550; 2551; 2552; 2553; 2554; 2555; 2556; 2557; 2558; 2559; 2560; 2561; 2562; 2563; 2564; 2565; 2566; 2567; 2568; 2569; 2570; 2571; 2572; 2573; 2574; 2575; 2576; 2577; 2578; 2579; 2580; 2581; 2582; 2583; 2584; 2585; 2586; 2587; 2588; 2589; 2590; 2591; 2592; 2593; 2594; 2595; 2596; 2597; 2598; 2599; 2600; 2601; 2602; 2603; 2604; 2605; 2606; 2607; 2608; 2609; 2610; 2611; 2612; 2613; 2614; 2615; 2616; 2617; 2618; 2619; 2620; 2621; 2622; 2623; 2624; 2625; 2626; 2627; 2628; 2629; 2630; 2631; 2632; 2633; 2634; 2635; 2636; 2637; 2638; 2639; 2640; 2641; 2642; 2643; 2644; 2645; 2646; 2647; 2648; 2649; 2650; 2651; 2652; 2653; 2654; 2655; 2656; 2657; 2658; 2659; 2660; 2661; 2662; 2663; 2664; 2665; 2666; 2667; 2668; 2669; 2670; 2671; 2672; 26

[illegible][illegible][illegible][illegible]

REFERENCE
T. C. C. 1994
11111111
National Institutes of Health, Mammalian Gene Collection (MGC)
Report 1310 (1999)
National Cancer Institute, Bethesda, Md.

[illegible]

10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532

F. T. O'NEILL, *IBM* 107-66, 1-66; E. J. COLEMAN, *IBM*,
 Health, Quality & Supervision, 8-66; G. G. 4,
 1-66; 107-66, 1-66.

[illegible][illegible]

Interactions of Health). Note: this is a NIH-MCJ Library.¹⁰

NAME	YR	278	195
HEIN	198	173	278

code	Material	Size	Year	Location	Notes
1001	1001	1001	1001	1001	1001
1002	1002	1002	1002	1002	1002
1003	1003	1003	1003	1003	1003
1004	1004	1004	1004	1004	1004
1005	1005	1005	1005	1005	1005
1006	1006	1006	1006	1006	1006
1007	1007	1007	1007	1007	1007
1008	1008	1008	1008	1008	1008
1009	1009	1009	1009	1009	1009
1010	1010	1010	1010	1010	1010
1011	1011	1011	1011	1011	1011
1012	1012	1012	1012	1012	1012
1013	1013	1013	1013	1013	1013
1014	1014	1014	1014	1014	1014
1015	1015	1015	1015	1015	1015
1016	1016	1016	1016	1016	1016
1017	1017	1017	1017	1017	1017
1018	1018	1018	1018	1018	1018
1019	1019	1019	1019	1019	1019
1020	1020	1020	1020	1020	1020
1021	1021	1021	1021	1021	1021
1022	1022	1022	1022	1022	1022
1023	1023	1023	1023	1023	1023
1024	1024	1024	1024	1024	1024
1025	1025	1025	1025	1025	1025
1026	1026	1026	1026	1026	1026
1027	1027	1027	1027	1027	1027
1028	1028	1028	1028	1028	1028
1029	1029	1029	1029	1029	1029
1030	1030	1030	1030	1030	1030
1031	1031	1031	1031	1031	1031
1032	1032	1032	1032	1032	1032
1033	1033	1033	1033	1033	1033
1034	1034	1034	1034	1034	1034
1035	1035	1035	1035	1035	1035
1036	1036	1036	1036	1036	1036
1037	1037	1037	1037	1037	1037
1038	1038	1038	1038	1038	1038
1039	1039	1039	1039	1039	1039
1040	1040	1040	1040	1040	1040
1041	1041	1041	1041	1041	1041
1042	1042	1042	1042	1042	1042
1043	1043	1043	1043	1043	1043
1044	1044	1044	1044	1044	1044
1045	1045	1045	1045	1045	1045
1046	1046	1046	1046	1046	1046
1047	1047	1047	1047	1047	1047
1048	1048	1048	1048	1048	1048
1049	1049	1049	1049	1049	1049
1050	1050	1050	1050	1050	1050
1051	1051	1051	1051	1051	1051
1052	1052	1052	1052	1052	1052
1053	1053	1053	1053	1053	1053
1054	1054	1054	1054	1054	1054
1055	1055	1055	1055	1055	1055
1056	1056	1056	1056	1056	1056
1057	1057	1057	1057	1057	1057
1058	1058	1058	1058	1058	1058
1059	1059	1059	1059	1059	1059
1060	1060	1060	1060	1060	1060
1061					

159 141 143 145 147 149 151 153 155 157 159 161 163 165 167 169 171 173 175 177 179 181 183 185 187 189 191 193 195 197 199 201 203 205 207 209 211 213 215 217 219 221 223 225 227 229 231 233 235 237 239 241 243 245 247 249 251 253 255 257 259 261 263 265 267 269 271 273 275 277 279 281 283 285 287 289 291 293 295 297 299 301 303 305 307 309 311 313 315 317 319 321 323 325 327 329 331 333 335 337 339 341 343 345 347 349 351 353 355 357 359 361 363 365 367 369 371 373 375 377 379 381 383 385 387 389 391 393 395 397 399 401 403 405 407 409 411 413 415 417 419 421 423 425 427 429 431 433 435 437 439 441 443 445 447 449 451 453 455 457 459 461 463 465 467 469 471 473 475 477 479 481 483 485 487 489 491 493 495 497 499 501 503 505 507 509 511 513 515 517 519 521 523 525 527 529 531 533 535 537 539 541 543 545 547 549 551 553 555 557 559 561 563 565 567 569 571 573 575 577 579 581 583 585 587 589 591 593 595 597 599 601 603 605 607 609 611 613 615 617 619 621 623 625 627 629 631 633 635 637 639 641 643 645 647 649 651 653 655 657 659 661 663 665 667 669 671 673 675 677 679 681 683 685 687 689 691 693 695 697 699 701 703 705 707 709 711 713 715 717 719 721 723 725 727 729 731 733 735 737 739 741 743 745 747 749 751 753 755 757 759 761 763 765 767 769 771 773 775 777 779 781 783 785 787 789 791 793 795 797 799 801 803 805 807 809 811 813 815 817 819 821 823 825 827 829 831 833 835 837 839 841 843 845 847 849 851 853 855 857 859 861 863 865 867 869 871 873 875 877 879 881 883 885 887 889 891 893 895 897 899 901 903 905 907 909 911 913 915 917 919 921 923 925 927 929 931 933 935 937 939 941 943 945 947 949 951 953 955 957 959 961 963 965 967 969 971 973 975 977 979 981 983 985 987 989 991 993 995 997 999 1001 1003 1005 1007 1009 1011 1013 1015 1017 1019 1021 1023 1025 1027 1029 1031 1033 1035 1037 1039 1041 1043 1045 1047 1049 1051 1053 1055 1057 1059 1061 1063 1065 1067 1069 1071 1073 1075 1077 1079 1081 1083 1085 1087 1089 1091 1093 1095 1097 1099 1101 1103 1105 1107 1109 1111 1113 1115 1117 1119 1121 1123 1125 1127 1129 1131 1133 1135 1137 1139 1141 1143 1145 1147 1149 1151 1153 1155 1157 1159 1161 1163 1165 1167 1169 1171 1173 1175 1177 1179 1181 1183 1185 1187 1189 1191 1193 1195 1197 1199 1201 1203 1205 1207 1209 1211 1213 1215 1217 1219 1221 1223 1225 1227 1229 1231 1233 1235 1237 1239 1241 1243 1245 1247 1249 1251 1253 1255 1257 1259 1261 1263 1265 1267 1269 1271 1273 1275 1277 1279 1281 1283 1285 1287 1289 1291 1293 1295 1297 1299 1301 1303 1305 1307 1309 1311 1313 1315 1317 1319 1321 1323 1325 1327 1329 1331 1333 1335 1337 1339 1341 1343 1345 1347 1349 1351 1353 1355 1357 1359 1361 1363 1365 1367 1369 1371 1373 1375 1377 1379 1381 1383 1385 1387 1389 1391 1393 1395 1397 1399 1401 1403 1405 1407 1409 1411 1413 1415 1417 1419 1421 1423 1425 1427 1429 1431 1433 1435 1437 1439 1441 1443 1445 1447 1449 1451 1453 1455 1457 1459 1461 1463 1465 1467 1469 1471 1473 1475 1477 1479 1481 1483 1485 1487 1489 1491 1493 1495 1497 1499 1501 1503 1505 1507 1509 1511 1513 1515 1517 1519 1521 1523 1525 1527 1529 1531 1533 1535 1537 1539 1541 1543 1545 1547 1549 1551 1553 1555 1557 1559 1561 1563 1565 1567 1569 1571 1573 1575 1577 1579 1581 1583 1585 1587 1589 1591 1593 1595 1597 1599 1601 1603 1605 1607 1609 1611 1613 1615 1617 1619 1621 1623 1625 1627 1629 1631 1633 1635 1637 1639 1641 1643 1645 1647 1649 1651 1653 1655 1657 1659 1661 1663 1665 1667 1669 1671 1673 1675 1677 1679 1681 1683 1685 1687 1689 1691 1693 1695 1697 1699 1701 1703 1705 1707 1709 1711 1713 1715 1717 1719 1721 1723 1725 1727 1729 1731 1733 1735 1737 1739 1741 1743 1745 1747 1749 1751 1753 1755 1757 1759 1761 1763 1765 1767 1769 1771 1773 1775 1777 1779 1781 1783 1785 1787 1789 1791 1793 1795 1797 1799 1801 1803 1805 1807 1809 1811 1813 1815 1817 1819 1821 1823 1825 1827 1829 1831 1833 1835 1837 1839 1841 1843 1845 1847 1849 1851 1853 1855 1857 1859 1861 1863 1865 1867 1869 1871 1873 1875 1877 1879 1881 1883 1885 1887 1889 1891 1893 1895 1897 1899 1901 1903 1905 1907 1909 1911 1913 1915 1917 1919 1921 1923 1925 1927 1929 1931 1933 1935 1937 1939 1941 1943 1945 1947

28 JUN 1999

DEFINITION	ACCESSION	VERSION	KEYWORDS
HS_5701392_17A_R1.1.1 Human ML160 (AV143415) Homo sapiens genomic clone (1076 bp) 1.2 Row D, DNA microarray.	AV661878	AV661878.1	01:5257061
US8.			
Source:			human.

ORGANISM
Home: reptiles
Eukaryote: Molasse, chlorophyll, cyanobacteria, eukaryotes
Mammals: Eukaryotes, eukaryotes, eukaryotes, eukaryotes
REFERENCE
1 (pages 1 to 44)
Mammals, 1966, Williams, J. C., Smith, R., Smart, J. L., and others.

Little Sequence Tagged Contigsets.

A sequence-tagged contigset (STC) is defined as

JOURNAL:
MEDLINE:
COMMENT:
Proc. Natl. Acad. Sci. U. S. A. '96 (17), 9759-9764 (1999)
99380589
Contact: Mahavir Singh, Wallace J., Hood L.

University of Washington
401 Union Anne Avenue North, Seattle, WA 98109, USA
Tel.: (206) 616 4618
Fax: (206) 616 4087

(Priority subscriptions and donations) - claims may be purchased from BACPA Rosecrans (at 1-800-435-4369) and for the 2007-2008 year from Rosecrans Expeditions (at 1-800-435-4369).
<http://www.bacpa-washington.org>

```
Set Point: 17  
Class: haw ends  
High quality sources stop: 44.  
Features  
Source Location/Qualities  
1..44  
/anthrism "humo sapiens"  
/chr_start "acm:606"  
/volume "Plate 10/6 fol 12 row 1"  
/volume lib "Rpt 11 Human Mals haw library"  
/sex "male"  
/photo Vector: pMAN-62 Strc 1: photo: Cto 2: back
```

pHAC ^{0.4,6} vector at E. coli sites ^a	
BASE CONTENT	158 d
ORIGIN	62 e ^b 164 f 164 f 164 f

Query Match 2.8%; Score 32; DB 13; Length 443;
Host Local Similarity 100.0%; Pred. No. 1.6e-05;
Matches 32; Conservative 0; Mismatches 0;
Indels 0; Gaps 0

—

217 CAGCAAAATGTCCTCAAGACGCAATAATAATA 184

Job time: 4971 Sec

Search completed: March 9, 2002, 04:42:44
Job time: 4971 sec

Sat Mar 9 09:57:22 2002

us-09-699-295-301.rst

Page 8

[illegible]

Dh	361	GTAAATCAATGACATGCTGTTTAAAGCAAGGCAAGTATCAATGCTGGTGGAGAGAGCTGG	420
Qy	421	gataagatctacacagatcttgccttgggtgggtggaatctctctcgaataagagattcttcgttcg	480
Dh	421	GATCAAGTCCCAAGAGATGAGTGGTGAGGATAAATGCTGCGGAGAAAGGATCTCAATGGTCATG	480
Qy	481	ctcagatgaactgaactgaacaaagaagacacatcaaaagagagcttctcttactctgctgc	540
Dh	481	CTCAGGAGACATGACCTGGAACAGAGAGCAAGCAAGCAAAAGAGCATGGTGTATCAATCTCGGC	540
Qy	541	cttgcgaatgagaaattcagaattaataaaactcctgctgaacagcaatgtaactaat	600
Dh	541	TTTGGCAATGGCAATATACAAATATATAAAATCTTGCTGGACACACAGATGTCACACTAAAT	600
Qy	601	gtctcttgaacaaagaagagacagctctgataagagctctgaataagcaggaagatga	660
Dh	601	GTCCTTGTAAATCAAAAGAGCAATCTTTGTAATAAGAGGCTGTAAATCTCAAGACATGAA	660
Qy	661	ctatgcttcaatctctctctgagaccttgccttgaagctgagaaattctcagatggaagat	720
Dh	661	TTGGTGTAATGGTTGTGGGAAATATGCTGATGTAATTAATTTTAAATATCAATGAGAAAT	720
Qy	721	agtaactctgacttactgctctctctgaataagaatgaatgaagctgagaaagactctctta	780
Dh	721	AGTACTGCAATACCAATATATATATATCAAGATAAATTAATGTCAAAGATATCTCTTA	780
Qy	781	tatagttatgagatctcgaattcaaaaagaagatataatgctcagacactgttactgtgtga	840
Dh	781	TATGGTATGATATCCAAATCAATCAAAAATCAAGCATGGCTGCACAAGAGGTATATGGTGA	840
Qy	841	ctatgagtaaaagagagagctgtctgaatttttactgagagaaagaagagattaaattgca	900
Dh	841	CATGAGCAAAAACAGCAAGATGCTGTGAAATTTTAAATCAAGAAAAAAGAGCAATTAATATCA	900
Qy	901	ctgaatagatatggaagactgctctcactactctctgataatgttgtaagacgaatata	960
Dh	901	CTGGAATAGATGGAAGCAAGCTGCTGCTCATATCTTGGTAATGTTGGTGAATGAAAGTAA	960
Qy	961	gtcaggtctctgactctgagcaaaatcttgatgtatctctctcagaggtctcactctgagag	1020
Dh	961	GTCAGGCTCTTACTGAGCAAAATATGATGATGATGCTCTCAAGATCTATCTGACAGAGG	1020
Qy	1021	gtcagagatataagattctctctcactcactcactcactcactcactcactcactcactc	1080
Dh	1021	GCTAGATAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG	1080
Qy	1081	aaatgaagaacatgctcaaaatctctctcgaagaacgaacgaacgaacgaacgaacgaac	1128
Dh	1081	AAAGCAAAACACATGCTAAAAATCTCTCTCAAAATCAGCAATCTCGGAA	1128
RESULT	5		
AX106594	AX106594	2040 bp	31-Apr-2001
DEFINITION	Sequence 375 from Patent WO0125272.		
ACCESSION	AX106594		
VERSION	AX106594.1	GI:1392265	
KEYWORDS	human.		
SOURCE	human.		
ORGANISM	Homo sapiens		
REFERENCE	Chakraborty; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eulipotyria; Primates; Catarrhini; Homidae; Homo. (bases 1 to 2040)		
ATTNOPS	Mo J., Strickly, V. A., Ford S.G. and Cheever, M. A. Compositions and methods for therapy and diagnosis of prostate cancer		
TITLE	Patent. WO 0125272 A 375 12 APR 2001; CORIAX CORPORATION (US) Location/Qualifiers		
JOURNAL	1. 2040 /organism: "Homo sapiens" /db_xref: "taxon:9606"		
FEATURES	source		
BASE COUNT	716 a 592 c 500 g 432 t		

